First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma
We present two cases of von Hippel–Lindau (VHL) disease-associated hemangioblastomas in the CNS treated with the newly approved HIF-2α inhibitor, belzutifan. The first case is a 31-year-old female with confirmed pathogenic germline VHL mutation who presented with multiple hemangioblastomas. The pati...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Taylor & Francis Group
2022-09-01
|
| Rangatū: | CNS Oncology |
| Ngā marau: | |
| Urunga tuihono: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0008 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|